These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35891442)

  • 1. Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak.
    Sonaglia A; Comoretto R; Pasut E; Treppo E; Del Frate G; Colatutto D; Zabotti A; De Vita S; Quartuccio L
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.
    Quartuccio L; Valent F; Pasut E; Tascini C; De Vita S
    Joint Bone Spine; 2020 Oct; 87(5):439-443. PubMed ID: 32445935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
    Machado PM; Lawson-Tovey S; Strangfeld A; Mateus EF; Hyrich KL; Gossec L; Carmona L; Rodrigues A; Raffeiner B; Duarte C; Hachulla E; Veillard E; Strakova E; Burmester GR; Yardımcı GK; Gomez-Puerta JA; Zepa J; Kearsley-Fleet L; Trefond L; Cunha M; Mosca M; Cornalba M; Soubrier M; Roux N; Brocq O; Durez P; Conway R; Goulenok T; Bijlsma JW; McInnes IB; Mariette X
    Ann Rheum Dis; 2022 May; 81(5):695-709. PubMed ID: 34972811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
    Favalli A; Favalli EG; Gobbini A; Zagato E; Bombaci M; Maioli G; Pesce E; Donnici L; Gruarin P; Biggioggero M; Curti S; Manganaro L; Marchisio E; Bevilacqua V; Martinovic M; Fabbris T; Sarnicola ML; Crosti M; Marongiu L; Granucci F; Notarbartolo S; Bandera A; Gori A; De Francesco R; Abrignani S; Caporali R; Grifantini R
    Front Immunol; 2022; 13():873195. PubMed ID: 35757699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of patients with rheumatic and musculoskeletal diseases during the coronavirus disease 2019 pandemic and the association of its relapse with infection: Across-sectional study.
    Zhang Y; Xu P; Huang J; Hu Z
    Int J Rheum Dis; 2024 Apr; 27(4):e15150. PubMed ID: 38661306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study.
    Liu S; Jin Z; Feng X; Da Z; Tang Y; Hu H; Wang D; Sun L
    Int J Rheum Dis; 2024 May; 27(5):e15166. PubMed ID: 38720417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study.
    Sarzi-Puttini P; Marotto D; Caporali R; Montecucco CM; Favalli EG; Franceschini F; Fredi M; Balduzzi S; Bazzani C; Bongiovanni S; Giorgi V; Batticciotto A; Cappelli A; Balzarini P; Dagna L; Sartorelli S; Ravagnani V; Tamanini S; Farah S; Faggioli P; Castelnovo L; Lurati AM; Galli M; Salaffi F
    J Autoimmun; 2021 Jan; 116():102545. PubMed ID: 32972804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
    Favalli EG; Monti S; Ingegnoli F; Balduzzi S; Caporali R; Montecucco C
    Arthritis Rheumatol; 2020 Oct; 72(10):1600-1606. PubMed ID: 32506699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.
    Tam LS; Tanaka Y; Handa R; Li Z; Lorenzo JP; Louthrenoo W; Hill C; Pile K; Robinson PC; Dans LF; Hsu LY; Lee SM; Cho J; Hasan ATMT; Salim B; Samreen S; Shaharir SS; Wong P; Chau J; Danda D; Haq SA
    Int J Rheum Dis; 2021 Jun; 24(6):733-745. PubMed ID: 33945214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
    Murray K; Quinn S; Turk M; O'Rourke A; Molloy E; O'Neill L; Mongey AB; Fearon U; Veale DJ
    Rheumatology (Oxford); 2021 Feb; 60(2):902-906. PubMed ID: 33164088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
    Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology.
    Zanetti A; Carrara G; Landolfi G; Rozza D; Chighizola CB; Alunno A; Andreoli L; Caporali R; Gerli R; Sebastiani GD; Valesini G; Sinigaglia L; Raffeiner B; Lomater C; Caprioli M; Fredi M; Romeo N; Cuomo G; Vadacca M; Scirè CA;
    Clin Exp Rheumatol; 2022 Nov; 40(11):2038-2043. PubMed ID: 35260224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
    Sengler C; Eulert S; Minden K; Niewerth M; Horneff G; Kuemmerle-Deschner J; Siemer C; Berendes R; Girschick H; Hühn R; Borte M; Hospach A; Emminger W; Armann J; Klein A; Kallinich T
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34312307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
    Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
    J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.
    Favalli EG; Bugatti S; Klersy C; Biggioggero M; Rossi S; De Lucia O; Bobbio-Pallavicini F; Murgo A; Balduzzi S; Caporali R; Montecucco C
    Arthritis Res Ther; 2020 Dec; 22(1):290. PubMed ID: 33380344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.
    Moradi S; Masoumi M; Mohammadi S; Vafaeimanesh J; Mohseni M; Mahdavi H; Aryannejad A
    Intern Emerg Med; 2021 Jun; 16(4):919-923. PubMed ID: 33128696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.